Abstract. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are being widely used as targeted therapy in non-small cell lung cancer (NSCLC), but most cases acquire drug-resistance in 9 months. However, the mechanisms of resistance are still not fully understood. Since it has been demonstrated that EGFR-TKI-mediated repression of downstream signaling cascades and apoptosis induction is a key mechanism through which EGFR-TKIs exert their cytotoxic effects, we reasoned that activation of downstream signaling pathways and changes in the expression of apoptosis-related proteins contribute to the acquired resistance to EGFR-TKIs. We analyzed the protein levels of p-Akt, Bcl-2, Bax between gefitinib-sensitive and gefitinib-resistant lung cancer cell lines and evaluated whether targeting the anti-apoptotic protein Bcl-2 induces cell apoptosis and further sensitizes resistant H1975 cells to gefitinib. The data showed that p-Akt was activated and accompanied by substantial Bcl-2 in the H1975 lung cancer cell line, whereas no evidence was observed in HCC827 cells. Using small interfering RNA (siRNA) to silence Bcl-2 in H1975 cells led to significant downregulation of Bcl-2 protein expression, decreased cell viability in vitro and induced intrinsic apoptosis confirmed by flow cytometry and PARP cleavage. In Bcl-2 siRNA-transfected cells, adding gefitinib further reduced the number of viable cells, induced apoptosis to a greater extent compared to either treatment alone. These preclinical data suggested that downregulation of Bcl-2 by RNAi in the gefitinib-resistant H1975 lung cancer cell line with T790M mutation enhanced the effects of gefitinib and may offer a novel therapeutic strategy for the treatment of NSCLC.

Introduction

Lung cancer is the most lethal cancer in the world. Non-small cell lung cancer (NSCLC), the majority form of lung cancer, is often in advanced stage when diagnosed and patients do not have the opportunity for surgical resection. Patients did not benefit much from traditional chemotherapy and radiotherapy; therefore the 5-year survival rate remained poor (1). In recent years, along with the invention of targeted therapy, more people benefit from the treatment and survive longer.

Gefitinib is a first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) which prevent the phosphorylation of EGFR as well as the signaling transduction (2). Clinically, only a subtype of patients is suitable to take EGFR-TKI as the major therapy. They were mostly Asians, females, non-smokers, adenocarcinomas and had sensitive mutation in exons encoding the tyrosine kinase domain of EGFR gene (3,4). However, to our disappointment, most patients could not escape a relapse when they took the drug for a median time of 9 months (5). A wide array of research has been done to explore the exact mechanism of acquired EGFR-TKI resistance. In 2005, the first case report on T790M mutation found that patient relapsed after receiving TKI drugs, Pao et al found that 50% of the cases progressed because they had the T790M mutation (6,7). Another 20% of secondary resistance was discovered in 2007 because of the amplification of the c-Met gene (8). Still, the remaining 30% are extensively investigated, for loss of PTEN gene, loss of IGF-binding protein, expression of epithelial membrane protein-1 (EMP-1), and activation of downstream EGFR signaling (9-13). Shaw et al reported in 2009 that in NSCLC patients with metastatic disease, who harbored EML4-ALK mutation, would become resistant to EGFR-TKI (14). However, the majority of extensive pre-clinical studies
invoking in vitro and in vivo experiments have not discovered new drug candidate having scientific merit for further development. Thus, we explored the untapped mechanism of acquired gefitinib resistance so as to provide a combinatorial strategy in H1975 gefitinib-resistant cell line using gefitinib as a main compound.

P-Akt was found elevated in many tumor tissue samples and cancer cell lines, including esophageal cancer, lung cancer and its expression is often related to poor clinical outcome and indicate the resistance of therapy (15-17). Since phosphoinositide 3-kinases (PI3K)/Akt pathway is vital in tumor development and progression, once activated, it would affect several downstream signaling pathways, such as proliferation, survival, anti-apoptotic, cell cycle and angiogenesis (18,19). Targeting the constitutively active Akt kinase and its key downstream molecules might provide a possible anticancer effect. Synergistic use of chemotherapy drugs with mTOR inhibitor exhibited great inhibition influence on renal cell carcinoma and was approved by FDA for use in patients with metastatic renal cell carcinoma (20). However, due to complicated interactions or compensatory upregulation of activated Akt, combining EGFR-TKI with mTOR inhibitor in lung cancer failed to reach the ideal result either in laboratory or in the latest clinical trials (21,22). It is, therefore, important to discover novel alternative Akt downstream targets which do not cause a negative feedback loop, allowing to reverse therapeutic resistance to TKI drugs. In 2004, Brown et al had found reduced expression of p27 was a novel mechanism of docetaxel resistance in breast cancer cells (23). Similarly, the downstream molecule Bim of Akt signaling is also involved in mediating EGFR-TKI-induced apoptosis in lung cancer cells (24). Knockdown of Bim was able to attenuate apoptosis induced by EGFR-TKI (24).

It is well known that gefitinib induces apoptosis in NSCLC cell line H3255 (2). Consequently, the development of resistance of cancer cells to TKI drugs may be a result of resistance to apoptosis. Bcl-2 is an Akt downstream anti-apoptotic protein belonging to the Bcl-2 family. In many tumor cells, such as breast cancer, and chronic lymphocytic leukemia, the knockdown Bcl-2 expression can induce cell apoptosis and even overcome drug resistance (25,26). We wondered whether gefitinib resistance was associated with the dysregulation of apoptosis in H1975 cell line. RNA interference is a more effective method to silence gene expression from RNA level to protein level compared with antisense method (27). We examined the influence of Bcl-2 small interfering RNA (siRNA) on the drug sensitization in H1975 cells. Our results revealed that the knockdown Bcl-2 gene expression by siRNA induced cell apoptosis in H1975 lung cancer cell line. Furthermore, gefitinib enhanced pro-apoptotic effect and reversed acquired EGFR-TKI drug resistance. Our data predicted a potential of a combined therapeutic approach with gefitinib and Bcl-2 siRNA for the treatment of EGFR-TKI-resistant H1975 cell line containing T790M mutation.

Materials and methods

Materials and reagents: The following monoclonal antibodies were used: Akt (Epitomics, CA, USA), p-Akt (Cell Signaling Technology, Danvers, MA, USA), Bcl-2 (Epitomics), Bax (Epitomics), caspase-3 (Epitomics), PARP-p110/85 (Epitomics), GAPDH (Epitomics). Goat anti-rabbit peroxidase-conjugated secondary antibody (Boster, Wuhan, China). The sequence of siRNA targeting Bcl-2 were: si-h-BCL2_001 sense, 5'-CGG AGGCUGGGAUGCCUUdTTG-3'; antisense, 3'-dTdTGC CUCCGACCUAAGGAA-5'; si-h-BCL2_002 sense, 5'-GG AUUGUGGCUCUCUUGUA dTTG-3'; antisense, 3'-dTdTCC UAACACGGAAGAACU-5'; si-h-BCL2_003 sense, 5'-GG AUGAUCUGAGUACUAA dTTG-3'; antisense, 3'-dTdTCC CUACUCGACUAGGACU-5'. SiRNA against Bcl-2 and a negative control siRNA were purchased from Guangzhou RiboBio Co. Ltd. (Guangzhou, China). Lipofectamine 2000 was obtained from Invitrogen (Carlsbad, CA, USA). Gefitinib was generously provided by AstraZeneca and was dissolved in DMSO in 20-mM concentration stored at -20°C. Drugs were diluted in fresh media immediately prior to use and the final DMSO concentration was <0.1%. MTT cell viability assay kit was obtained from Sigma-Aldrich (St. Louis, MO, USA). DAPI was purchased from Beyotime Institute of Biotechnology (Shanghai, China). Annexin V-FITC apoptosis detection kit was obtained from KeyGen Biotech Co. (Nanjing, China).

Cell culture. The human lung cancer H1975 and HCC827 cell lines were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). H1975 cell line was cultivated in DMEM high-glucose medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco), HCC827 cell line was grown in RPMI-1640 medium (Gibco) supplemented with 10% fetal bovine serum (Gibco). Cells were incubated in a humidified incubator at 37°C with 5% CO2 atmosphere and maintained in a logarithmic growth phase for all the experiments.

Transient transfection. To study the uptake of cy3-conjugated scrambled negative control siRNA, after plating 2.5x104 cells well in 24-well plates, transfection efficiency of siRNA at various concentrations was observed by fluorescence microscopy. We chose 50 nM which shows >80% transfection efficiency in the following experiments. For confirmation of downregulation of Bcl-2 protein, three siRNA oligonucleotides directed against Bcl-2 and a negative control siRNA were tested for effectiveness of protein knockdown. In brief, 1x104 cells were plated in 6-well plates, incubated for 24 h and transfected with siRNA at 50 nM using Lipofectamine 2000 reagent and OPTI-MEM reduced serum media (Gibco) according to the manufacturer’s instructions. Later (4-6 h), OPTI-MEM media was aspirated and DMEM fresh media containing 10% FBS was added. At 48 h after transfection, cellular expression of Bcl-2 was determined by western blot analysis.

MTT assay. Cell viability assay was performed with MTT cell viability assay kit. Cells were seeded into 5 replicate wells of each group, at a density of 6x103 viable cell per well in 96-well plates. Allowed to attach for 24 h, transfection was done. Forty-eight hours later, various concentrations of gefitinib were added and cells were incubated for another 24 h. At the indicated time, 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) was added to incubate for 4 h. Then media were aspirated, 100 µl DMSO was added. Cells were incubated for 10 min at 37°C with gentle shaking. The
absorbance was then read at 490 nm with a 96-well microplate reader (Bio-Rad). The values in the siRNA treated cells were normalized to the values of control to as determine the percentage of viability. Each assay was performed in triplicate. The inhibition rate (IR) was calculated according to equation: IR = [A490 (control) - A490 (treatment)]/[A490 (control) - A490 (zero)] x 100%.

A490 (control) stands for the absorbance in control group. A490 (treatment) was the absorbance in the drug-treated or siRNA groups. A490 (zero) means the absorbance in the group with no cells.

**Statistical analysis.** Statistical analysis was carried out using SPSS software, version 17.0 (Chicago, IL, USA). Data are presented as mean ± SD from at least three experiments. Results were analyzed using Student's t-test and p-values were indicated where appropriate in the figures and in their legends. A p<0.05 was considered statistically significant.

**Results**

**Gefitinib-induced cytotoxicity is substantially reduced in gefitinib-resistant H1975 cell line compared with gefitinib-sensitive HCC827 cell line.** Lung cancer H1975 cell line is an established cell line bearing T790M mutation besides L858R mutation and is being used as a model for acquired resistance to EGFR-TKI. In this experiment, we chose HCC827 lung cancer cell line containing exon 19 deletion as a sensitive control. To measure the growth inhibitory action of gefitinib and to confirm each cell line as either sensitive or resistant, we performed MTT assays. For each cell line, cells were incubated for ≤48 h at indicated doses of gefitinib (0, 0.001, 0.01, 0.1, 1, 10 or 100 µmol/l). The results (Fig. 1A and B) demonstrated that gefitinib exhibited time- and dose-dependent inhibition effect on HCC827 cell line, and slightly inhibited the proliferation of H1975 cells. After 24-h exposure to gefitinib, H1975 gefitinib-resistant subtype exhibited greater resistance to gefitinib than did HCC827 cells (IC_{50} 35.75±0.77 µmol/l vs 0.003±0.18 µmol/l, respectively).

**Akt activation and downstream protein expression in different cell lines.** To test whether PI3K/Akt signaling cascade activation exists in cells with acquired resistance to gefitinib, we used immunoblotting to test expression of several proteins between gefitinib-resistant and gefitinib-sensitive cell lines. As expected, phosphorylated Akt was elevated in H1975 cell line compared with HCC827 cell line (Fig. 1C). Since we and others had found that gefitinib induce apoptosis and downregulate phosphorylated Akt expression in HCC827 cell line, we presumed that acquired gefitinib resistance might be due to the overexpression of certain inhibitor proteins of apoptosis which belong to the Akt downstream of signaling cascade (2). We compared the basic level of Bcl-2 family apoptosis-related proteins in two cell lines. Indeed, we found abundant anti-apoptotic Bcl-2 protein in H1975 cells, whereas no evidence was detected in HCC827 cells (Fig. 1C). There was no significant difference in the expression of pro-apoptotic Bcl-2 associated X protein (Bax) (Fig. 1C).

**Knockdown of the Bcl-2 gene in H1975 lung cancer cell line.** Based on the above results, we performed RNA interference methodology to downregulate Bcl-2 protein expression in H1975 cell line. We used cy3-conjugated siRNA to verify the transfection efficiency though fluorescence microscopy, the transfection efficiency in this cell line can reach >80% when...
siRNA concentration is 50 nM. After 48 h of transfection, the effect of siRNA on the protein level was assessed (Fig. 2A). A small amount of Bcl-2 in transfected group was detected from the immunoblotting. The suppression lasted for 72 h post-transfection. We chose siRNA-Bcl-2_003 as the most efficacious one for the following experiments (Fig. 2A). No Bcl-2 downregulation was detected in the negative siRNA group or in mock transfected cells (Fig. 2B), and the expression of protein Bax had not changed (Fig. 2B), indicating a specific and effective function, thus excluding that the effects were due to the upregulated Bax.

Bcl-2 siRNA increases gefitinib sensitivity. We examined the effects of siRNA mediated silencing of Bcl-2 protein expression on the proliferation of H1975 lung adenocarcinoma cells. After being transfected with Bcl-2 siRNA for 48 h, viable cells were reduced to 58.1% compared with the untreated control group (Fig. 3A). Although negative siRNA group and mock transfected cells exhibited minor killing effect, there was no statistical significance (p>0.05). The results showed that downregulating Bcl-2 expression was able to restore the effect of gefitinib in H1975 cells, Bcl-2 siRNA transfectants had higher IR than negative siRNA transfectants or mock cells (p<0.05). After a 48-h period allowing silencing of Bcl-2, H1975 cells were further exposed to a series concentrations of gefitinib (0, 0.5, 1, 5, 10, 50 or 100 µmol/l) for 24 h. As shown in Fig. 3B, we observed that combination treatment significantly augmented IR ~4.6-fold compared with control group with gefitinib (IC\textsubscript{50} 7.07±0.38 vs 32.47±0.71 µmol/l, respectively) and 4.3-fold compared with negative siRNA plus gefitinib (IC\textsubscript{50} 7.07±0.38 vs 30.27±0.61 µmol/l, respectively). Results indicated that combining Bcl-2 siRNA and gefitinib induced synergistic inhibitory effect on H1975 cell proliferation and viability.

Effect of Bcl-2 siRNA on the nuclear morphology change. We investigated whether the anti-proliferation effect of Bcl-2 siRNA in H1975 cells was due to the induction of apoptosis, and whether the knockdown of Bcl-2 might sensitize the cells to undergo apoptosis in response to gefitinib. To provide
confirmatory evidence, DAPI staining was performed to detect nuclear morphological changes of the H1975 cells being transiently transfected in the presence or absence of gefitinib.

We chose 5 µmol/l according to the IC\textsubscript{50} and also because this is a concentration that can be achieved in serum of patients being treated with gefitinib for short period (29). As shown in Fig. 4A, cells transfected with siRNA targeting Bcl-2 for 48 h underwent characteristics of apoptosis, including chromatin condensation and nuclear DNA fragmentation. When followed by 5 µmol/l gefitinib administration for 24 h, the nuclear change became more obvious. Inversely, untreated control cells, merely suffering higher dose of gefitinib (20 µmol/l) and cells transfected with negative siRNA all showed only slight signs of apoptosis.

Effect of Bcl-2 siRNA on cellular apoptosis. To further investigate the exactly apoptosis rate among different groups, we performed flow cytometry. The Annexin-V-FITC assay was aimed to distinguish whether the reduction in cell viability was due to apoptosis or necrosis. As seen in Fig. 4B, after Bcl-2 siRNA treatment, the rate of early apoptotic cells increased from 7.98 in control group to 21.35%. This difference is statistically significant (p<0.05). The percentage of late apoptotic cells was also augmented. To determine whether the time to add gefitinib impacted on the synergistic effect, we evaluated different groups according to the time-points that gefitinib was added. Cells were treated with 5 µmol/l gefitinib at the time of transfection end, 24 h later or 48 h after transfection. When followed by 5 µmol/l gefitinib addition 48 h after transfection, the early apoptotic fraction increased to a greater extent, from 21.35% in the absence to 29.27% in the presence. Our results showed only the group that added gefitinib ≥48 h after transfection had synergistic function. This synergistic effect could not be seen in other groups when gefitinib was added at an earlier time either immediately after transfection or 24 h later. Results above suggested that knockdown of

Figure 2. Effects of Bcl-2 small interfering RNA on Bcl-2 protein expression in H1975 cell line. (A) Comparison of the silencing effect of Bcl-2 siRNA001, Bcl-2 siRNA002 and Bcl-2 siRNA003 on NSCLC H1975 cell line. Cells were transfected with 50 nM Bcl-2 siRNAs and 48 h post transfection, lysed and 40-µg proteins was used for detection. (B) Specific inhibition of Bcl-2 protein expression was tested. Cells without treatment (control), negative siRNA transfected (negative siRNA), mock transfected (mock, all reagents except for siRNA) were used as controls. (C) Analysis of protein level of each Bcl-2 siRNA group with untreated control group. (D) Bcl-2 protein expression was significantly decreased in Bcl-2 siRNA003-treated group while no distinctive change was observed in other control groups. Bcl-2 siRNA does not affect the expression of Bax protein. GAPDH was used as the internal control. The histogram shows the mean ± SD for triplicate analysis. *p<0.05 vs. control group.

Figure 3. Bcl-2 siRNA inhibits cell proliferation and sensitizes H1975 cell line to gefitinib. (A) Cells were incubated with 50 nM Bcl-2 siRNA, negative siRNA or only Lipofectamine 2000 for 48 h. MTT assay was used to determine the cell proliferation inhibition rate. *p<0.05 vs. negative siRNA group while †p<0.05 vs. mock group. (B) Cells were incubated with different doses of gefitinib for 24 h after being transfected with Bcl-2 siRNA or not. *p<0.05 vs. negative siRNA with gefitinib while †p<0.05 vs. gefitinib only group.
ZOU et al.: KNOCKDOWN OF Bcl-2 INCREASES SENSITIVITY TO EGFR-TKI

Bcl-2 protein expression in H1975 lung cancer cell line can suppress cell proliferation via apoptosis induction. It also demonstrated that synergy between Bcl-2 siRNA and gefitinib was augmented by optimizing drug scheduling with superior effects when gefitinib was administered 48 h after transfection at the time that Bcl-2 had been successfully knocked down. The data coincided with the hypothesis that Bcl-2 expression level is associated to the sensitivity of EGFR-TKI drugs.

**Effect of Bcl-2 siRNA activated caspase-3 and increased PARP cleavage through regulating intrinsic mitochondrial pathways of apoptosis.** The pro-apoptotic effect of Bcl-2 siRNA was further confirmed by examining the total and cleavage protein of caspase-3 and its downstream substrate PARP. As seen in Fig. 5A once cells were treated with Bcl-2 siRNA will activate pro-caspase-3 then induce 17-kDa active caspase-3, PARP was cleaved from its 116-kDa intact form into 85-kDa cleaved fragment. Cleaved PARP which is a marker of caspase-mediated early apoptosis was increased in Bcl-2 siRNA treated cells and those followed by gefitinib treatment after transfection (30). Inversely, not much cleaved PARP could be seen in the other groups. From the experiment, we observed onset of the Bcl-2

Figure 4. Cell nuclear morphological change and determination of apoptosis rate after downregulation of Bcl-2 expression in H1975 cell line in the presence or absence of gefitinib. (A) Nuclear morphology of H1975 cells were stained with DAPI. Images from left to right: cells without treatment (control); cells with 20 µmol/l gefitinib for 24 h (gefitinib); negative siRNA transfectants (negative siRNA); Bcl-2 siRNA transfectants (Bcl-2 siRNA); Bcl-2 siRNA transfected followed by 5 µmol/l gefitinib for 24 h (Bcl-2 siRNA+gefitinib). Upon treatment with Bcl-2 siRNA, cells showed characteristic apoptotic morphology of nuclear DNA condensation, marginalization or fragmentation while no observable change could be seen from negative siRNA group or untreated group. When followed by 5 µmol/l gefitinib administration for 24 h, the nuclear change became more significant (magnification, x200). (B) Flow cytometry analysis using Annexin V-FITC and propidium iodide double staining was performed to detect the apoptosis ratio. Cells transfected with Bcl-2 siRNA induced apoptosis and was further enhanced by combination of Bcl-2 siRNA plus gefitinib. (C) Comparison of the total apoptosis rate including early and late apoptosis populations. Early apoptotic cells were positive for Annexin V-FITC and negative for PI. Late apoptotic cells were positive for both Annexin V-FITC and PI. The data are presented as means ± SD for triplicate analysis per group. *p<0.05 vs. control group and **p<0.05 vs. Bcl-2 siRNA group.
siRNA process of intrinsic mitochondrial way of caspase-dependent apoptosis which was consistent with the finding in other cell lines (31,32). We found that gefitinib alone and Bcl-2 siRNA alone did not inhibit or stimulate Akt phosphorylation in H1975 cell line which indicated that no direct feedback loop exists between Bcl-2 and p-Akt; however, when siRNA targeting Bcl-2 followed by addition of 5 µmol/l gefitinib, the phosphorylation of Akt was reduced while the amount of total Akt expressed was consistent with the treatment results of Bcl-2 siRNA or gefitinib.

Discussion

Activated Akt expression manifests poor clinical outcome and confer chemotherapy and radiotherapy resistance in many cancer types including NSCLC, and neuronal cells (16,33). Consistent with previous literature, our results show that compared with TKI-sensitive HCC827 lung cancer cell line, the level of p-Akt in TKI-resistant H1975 lung cancer cell line was elevated. In the former studies, it was found that combining EGFR-TKI with specific inhibitors of the Ras or PI3K pathways exerted different effects in several lung cancer cell types, which might correlate with the diverse expression of downstream proteins (34). Compared with LY294002 which is a potent inhibitor of PI3Ks, bortezomib, a proteasome inhibitor used in an established EGFR-TKI-resistant cell line, induced a significant inhibition of cancer cell growth and increased apoptosis suggesting that besides interfering with Akt signaling, other molecular mechanisms were involved in overcoming resistance to anti-EGFR therapies (35). Deregulation of the Akt-dependent pathway has been well documented in a variety of human tumors (23,24). We were eager to know whether the activation of Akt and its downstream cascade differs in NSCLC cell lines with different response to EGFR-TKI. We focused on apoptosis pathway downstream of Akt aiming to avoid the negative feedback induced by mTOR inhibition (36). We postulated that tyrosine kinase inhibitor resistance in lung cancer H1975 cell line bearing T790M mutation might result from elevated p-Akt and the deregulation of apoptosis cascade. The reasons for apoptosis evasion can be divided as follows: i) overexpression of anti-apoptotic protein, such as Bcl-2, Bcl-xl, ii) lack of pro-apoptotic protein, such as Bax, Bad, iii) higher expression of surviving genes, for instance, survivin (37). In our experiments, we examined protein level of apoptosis-related proteins and found there was no distinction in Bax protein expression but a distinguishable difference in Bcl-2 protein expression between two cell lines of NSCLC on the basis of obvious discrepancy in sensitivity to...
gefitinib. Our results were in line with previous findings that Bcl-2 protein expression level would increase when cells were treated with certain chemotherapy drugs and became resistant (38,39). The finding was unexpected since Bcl-2 is rarely expressed in NSCLC, unlike the level of Bcl-2 that is abundant in small cell lung cancer (SCLC) (40). We thus hypothesized that substantial Bcl-2 might be related to gefitinib resistance. Therapy targeted at anti-apoptotic protein from Bcl-2 family might reaktivate the apoptosis signaling pathway.

The function of Bcl-2 in Bcl-2 overexpressing tumors such as lymphomas and SCLC have been explored. Clinically, chronic lymphocytic leukemia (CLL) is suitable for targeting by imatinib. A great body of basic experiments investigated the possible mechanism of acquired drug-resistance to find new approaches to resensitize the malignant cells to the treatment. Bcl-2 overexpression is a hallmark in CLL refractory patients (41). Phase I study of Navitoclax (ABT-263) or pan Bcl-2 family inhibitor Obatoclax in CLL patients with relapsed disease showed that Bcl-2 could be a valid therapeautic target (41,42). Similar phase I clinical studies had been done in SCLC, the Bcl-2 family genes were greatly amplified and had achieved good results with acceptable adverse effect (43,44). Similar results were confirmed in hepatocarcinoma cells resistant to LCL161 with a combination of Bcl-2 siRNA and LCL161 (45). In our study, data confirmed that the cytotoxic and pro-apoptosis effects in H1975 cell line induced by Bcl-2 siRNA alone could be enhanced when administered together with gefitinib thus reversing acquired EGFR-TKI resistance.

Our data agree with that reported by Fan and co-workers who demonstrated that the established early TKI resistant cell lines exhibited dependence on activation of Bcl-2/ Bcl-x1 signaling (46). They also found that when using Bcl-2 homology domain 3 mimetic agents ABT-737 could eradicate the tumor cells evading TKI drugs. Contrary to us, they found that mere Bcl-2 siRNA could not induce dramatic reduction in the early TKI-resistant tumor cells. Dual knockdown of Bcl-2/Bcl-x1 manifested more advantageously in cytotoxicity comparing to single intervention. We propose the disparity might lie in the different cell models, the very ‘early’ molecular events found in their study were probably not the same with the protein changes discovered by us in established cell lines.

However, the precise mechanism for increased Bcl-2 expression in H1975 cell line is still unclear. One potential mechanism may be that micro-RNAs involved in regulating target genes include Bcl-2 (47-49). A panel of miRNAs (miR-16, miR-143) suppressed by estradiol (E2) dramatically induce Bcl-2 expression in breast cancer cells (47). Wang et al determined that miR-181d may act as a giroma suppressor by targeting K-ras and Bcl-2 (48). Similar observation was reported where miR-136 was downregulated in human glioma and lost the capacity to repress anti-apoptotic genes, AEG-1 and Bcl-2 (49). In addition, hepatitis B virus pre-S2 large mutant surface antigen (HBV pre-S2D) increased Bcl-2 expression in hepatocellular carcinoma cells (50). Therefore, further examination of the specific mechanism that Bcl-2 overexpressed in H1975 lung cancer cells are undertaken in our laboratory.

Only a few studies have focused on combining Bcl-2 siRNA with targeted therapy except in CLL. In this study, we confirmed the effect of Bcl-2 siRNA on EGFR-TKI acquired resistant H1975 lung cancer cell line. Although we have verified that Bcl-2 was vital for cell proliferation, anti-apoptotic, inducing acquired drug resistance in H1975 cell line, there are still certain limitations which need further clarification. However, notwithstanding the limitation, this study does suggest the effect of Bcl-2 siRNA on sensitizing TKI acquired resistant cell line to gefitinib.

In conclusion, endogenous level of Bcl-2 can predict the cell sensitivity to EGFR-TKI gefitinib and is an important determinant in gefitinib resistance. Our in vitro study suggested that knockdown the expression of Bcl-2 by siRNA can reverse drug resistance to gefitinib in H1975 lung cancer cell line harboring T790M mutation. Thus, these findings provide a new concept for the development of novel therapeutic approaches in the treatment of refractory and relapsed patients who are no longer sensitive to EGFR-TKI drugs. Combination of common-used therapy with one targeted to downstream blocking may raise new hope for cure.

Acknowledgements

This study was supported by National Natural Science Foundation of China (no. 81172187) and in part by grant from the Wujieping Foundation, China (no. 320.6720.10010).

References

Signaling networks


